Genmab A/S Sponsored ADR $GMAB Stock Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA boosted its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 8.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,150,854 shares of the company’s stock after acquiring an additional 84,927 shares during the period. Pictet Asset Management Holding SA owned approximately 0.18% of Genmab A/S worth $41,044,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. First Trust Advisors LP increased its holdings in shares of Genmab A/S by 84.3% in the first quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after purchasing an additional 1,126,069 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after buying an additional 921,700 shares in the last quarter. SummitTX Capital L.P. bought a new position in Genmab A/S in the 1st quarter valued at $2,263,000. Legacy Wealth Asset Management LLC increased its stake in shares of Genmab A/S by 164.1% in the 2nd quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock valued at $2,806,000 after buying an additional 63,484 shares during the period. Finally, Advisors Preferred LLC acquired a new stake in shares of Genmab A/S in the 1st quarter valued at $1,361,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Key Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $70 price target, above the share price in the supplied market data. MarketBeat report
• Neutral Sentiment: Genmab disclosed an increase of 164,828 shares following employee warrant exercises. The issuance creates some dilution, though the announcement does not indicate its likely financial impact. Capital increase announcement
• Neutral Sentiment: Genmab reported managerial and associated-person transactions, but the supplied notice provides no transaction details to indicate whether they were purchases or sales. Managerial transaction announcement
• Negative Sentiment: HC Wainwright cut several quarterly and annual EPS forecasts, including its FY2027 estimate to $1.60 from $2.15. The firm still rates the stock Buy, but the downward revisions could pressure sentiment.
• Negative Sentiment: Reported short interest rose 46.4% from mid-October to 9.66 million shares as of October 30, suggesting increased bearish positioning. It was still about 1.6% of shares, with a 1.2-day short-interest ratio.

Genmab A/S Price Performance

GMAB stock opened at $54.07 on Wednesday. The company has a market capitalization of $33.74 billion, a P/E ratio of 42.92, a price-to-earnings-growth ratio of 2.25 and a beta of 0.73. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.43 and a current ratio of 2.45. Genmab A/S Sponsored ADR has a 52-week low of $23.62 and a 52-week high of $59.97. The business has a 50-day simple moving average of $40.05 and a two-hundred day simple moving average of $31.33.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.20. Genmab A/S had a return on equity of 13.67% and a net margin of 16.97%. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Research analysts expect that Genmab A/S Sponsored ADR will post 1.28 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on GMAB. Weiss Ratings raised Genmab A/S from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday. Guggenheim boosted their price target on Genmab A/S from $58.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, October 30th. New Street Research set a $43.00 target price on Genmab A/S in a research report on Wednesday, July 22nd. JPMorgan Chase & Co. raised Genmab A/S from a “neutral” rating to an “overweight” rating in a research note on Monday, October 26th. Finally, Morgan Stanley increased their price target on Genmab A/S from $42.00 to $57.00 and gave the stock an “equal weight” rating in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $53.61.

Genmab A/S Profile

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.